Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine ...

Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...

Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie.Light ...

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

Korro Bio, Inc. (NASDAQ:KRRO), a pharmaceutical company specializing in preparations with a market capitalization of $285 million, announced today that Vineet Agarwal, the company's Chief ...

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...

Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore ...

Korro Bio, Inc. CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...